STOCK TITAN
  1. Home
  2. Sec-filings
  3. SOPH
  4. [Form 4] SOPHiA GENETICS SA Insider Trading Activity

SOPHiA GENETICS (SOPH) CTO sells 10,000 shares in planned August trades

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) reported that Chief Technology Officer Abhimanyu Verma sold a total of 10,000 Ordinary Shares in two open-market transactions. On August 19, 2026, he sold 5,000 shares at $8.20 per share, and on August 24, 2026, he sold 5,000 shares at $8.80 per share. Both transactions were executed under a duly adopted Rule 10b5-1(c) trading plan, indicating they were pre-arranged.

Positive

  • None.

Negative

  • None.
Insider Verma Abhimanyu
Role Chief Technology Officer
Sold 10,000 shs ($85K)
Type Security Shares Price Value
Sale Ordinary Shares F1 5,000 $8.80 $44K
Sale Ordinary Shares F1 5,000 $8.20 $41K
Holdings After Transaction: Ordinary Shares — 172,171 shares (Direct)
Footnotes (1)
  1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
Shares sold August 19, 2026 5,000 Ordinary Shares Sale of non-derivative shares at $8.20 per share by CTO Abhimanyu Verma
Price per share August 19, 2026 $8.20 per share Open-market or private sale of 5,000 Ordinary Shares
Shares sold August 24, 2026 5,000 Ordinary Shares Sale of non-derivative shares at $8.80 per share by CTO Abhimanyu Verma
Price per share August 24, 2026 $8.80 per share Open-market or private sale of 5,000 Ordinary Shares
Total shares sold in reported period 10,000 Ordinary Shares Sum of two sale transactions reported in this Form 4
Rule 10b5-1(c) regulatory
"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
trading plan regulatory
"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."
A trading plan is a written set of rules an investor follows about what to buy or sell, when to enter and exit positions, and how much risk to accept—like a travel itinerary that maps the route, stops, and budget before a trip. It matters because it helps remove emotional decisions during market swings, enforces discipline, and makes performance easier to review and improve, reducing the chance of costly impulsive moves.
Ordinary Shares financial
"security_title: "Ordinary Shares""
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
non-derivative financial
"transaction_type: "non-derivative""

FAQ

What insider transactions did SOPH report for Abhimanyu Verma?
SOPHiA GENETICS SA reported that CTO Abhimanyu Verma sold a total of 10,000 Ordinary Shares in two transactions, one on August 19, 2026 and one on August 24, 2026, at prices of $8.20 and $8.80 per share, respectively, under a Rule 10b5-1 plan.

How many SOPH shares did Abhimanyu Verma sell on August 19, 2026?
On August 19, 2026, CTO Abhimanyu Verma sold 5,000 Ordinary Shares of SOPHiA GENETICS SA at a price of $8.20 per share in an open-market or private transaction reported with code S.

What was the SOPH share sale reported on August 24, 2026?
On August 24, 2026, Abhimanyu Verma sold 5,000 Ordinary Shares of SOPHiA GENETICS SA at a price of $8.80 per share, reported as a sale transaction (code S) of non-derivative securities.

Were Abhimanyu Verma’s SOPH share sales under a Rule 10b5-1 plan?
Yes. Each reported transaction carries a footnote stating it was made pursuant to a duly adopted trading plan under Rule 10b5-1(c), and the filing’s Rule 10b5-1 checkbox is marked true, indicating the sales were pre-arranged under such a plan.

How many SOPH shares in total did Abhimanyu Verma sell in this Form 4?
Across the two reported transactions, Abhimanyu Verma sold a total of 10,000 Ordinary Shares of SOPHiA GENETICS SA: 5,000 shares at $8.20 per share and 5,000 shares at $8.80 per share.

What is Abhimanyu Verma’s role at SOPHiA GENETICS SA mentioned in the Form 4?
The Form 4 identifies Abhimanyu Verma as an officer of SOPHiA GENETICS SA, serving as Chief Technology Officer. The reported transactions involve his holdings of the company’s Ordinary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Verma Abhimanyu
(Last)(First)(Middle)
C/O SOPHIA GENETICS SA
LA PIECE 12
(Street)
ROLLE1180
(City)(State)(Zip)
SWITZERLAND
(Country)		2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Technology Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares08/19/2026S5,000(1)D$8.2177,171D
Ordinary Shares08/24/2026S5,000(1)D$8.8172,171D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
Remarks:
/s/ Elimara Brunetto as Attorney-in-fact for Abhimanyu Verma08/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR